FXR agonism with OCA has been shown to lead to a reduction in monocyte chemoattractant protein-1 mRNA expression in NASH models, decreasing inflammatory cell infiltration and further improving fibrosis.[23] In summary, OCA exhibits antifibrotic, anti-cholestatic, and anti-inflammatory properties.[16]. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatohepatitis.